Celyad Oncology specializing in cancer treatment goes public
Celyad Oncology has just had a clinical trial validated by the FDA, a major milestone in the development of Nasdaq-listed biotech company. On Tuesday, July 14th, the biotech stock price listed on the Brussels Euronext and the Nasdaq had gained 11.7%, a sharp rise that gave it visibility until Thursday, July 16th, when the share price climbed a further 2.45% to $11 (€9.6).
“This is a decisive moment for our company,” said Filippo Petti, the director of Celyad Oncology, a Belgian biotech company founded in 2004 and located in the French-speaking commune of Mont-Saint-Guibert in the Walloon Region. Last week in the United States, the FDA (Food and Drug Administration) validated the launch of a new clinical trial of the company, to conduct a study around a new approach in the treatment of cancer.
The startup Celyad Oncology is one of those biotech players to innovate in the sector, specializing in particular in a very special and delicate case for patients whose treatment does not respond: relapsing multiple myeloma. Celyad Oncology was asking the US Drug Administration to validate a new phase of testing in which the biotech will test a new process that does not involve genome editing (corresponding to the localized modification of genomic sequences, which is a dangerous process).
If you want to find more details about Celyad Oncology’s recent developments and the trends in the biotech sector, download for free the Born2Invest mobile app. Read the latest business news with our companion app and stay on top of the market.
Celyad Oncology’s title was up 11% after the FDA announced its approval
On Tuesday, July 14th, when the FDA announced the approval, the biotech stock price listed on the Brussels Euronext and the Nasdaq had gained 11.7%, a sharp rise that gave it visibility until Thursday, July 16th, when the share price climbed a further 2.45% to $11 (€9.6). For Boursorama analysts, the 3-month price target is $24.5 (€21.36), which demonstrates the company’s potential in cancer research.
“Today’s announcement demonstrates our ability to advance in parallel several ready-to-use allogeneic candidates based on different technologies not involving genome editing into clinical research,” said the company, adding that “for the CYAD-211 program, our team has enabled the project to progress from the proof of concept phase to an effective IND in a very short period of time, less than two years.”
The biotech sector is a fast-growing sector
For several months now, Société Générale Bank has grouped 48 of the sector’s best-performing biotech companies under the “Next Biotech” index. In 2020, it is indicative of strong growth in the biotech market, which has taken advantage of the health crisis to have numerous growth levers at its disposal.
Despite the stock market crash in early March, a fund like Pictet Biotech has risen 16% since the beginning of the year and 37% since March. In recent days, US biotech Moderna Therapeutics has been in the spotlight, as its research into a vaccine against COVID-19 has taken another major step forward with the validation of a final test phase.
Last month, Presse Citron gave a comprehensive report on the similar situation in the healthtech market, those health-care startups that have taken advantage of 2020 to attract more investors. The first quarter of 2020 set a record for fundraising in the sector, with $8.2 billion in new money raised worldwide, a marked increase of 76 percent compared to the first quarter of last year.
(Featured image by DarkoStojanovic via Pixabay)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PRESSECITRON, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Featured1 week ago
Peridot Solar Takes Over a 135 MW Agrivoltaic Project in Sicily from Iqony Solar Energy Solutions Italia
Biotech2 days ago
Better Opens a Subsidiary in Spain and Projects 5 Million Revenues Before 2025
Featured1 week ago
Self-Consumption Revolution in Spain Plunges Electricity Demand to a 20-Year Low
Featured2 weeks ago
P&G SGR and UpsideTown Launch Energy Town Fund Dedicated to Renewables